The quarter in brief, January -
January -
** Net sales:
** Operating income:
** Net income for the period:
** Earnings per share:
Summary of the quarter
** 39% sales growth
** Net income for the period improved by
** Organization strengthened with new Head of Sales
** New distributor in
** Strategy for sustainable growth developed and implemente
CEO words
Positive start to 2022
Glycorex had a positive start to 2022. Sales in the first quarter of the year increased by 39 percent to
Market development
Many of our markets developed positively in the quarter. In
As part of strengthening our sales capacity and sharpening our commercial focus, we have recruited
Going for Growth (G4G) - Strategy for Sustainable Growth
During the first quarter of the year, we have worked intensely to iden- tify activities and areas that can establish sustainable growth for the company. Our ambition is for Glycorex to begin a long-term growth journey by taking advantage of the obvious opportunities that our unique technology offers. The areas we will prioritize are as follows:
G1. Growing globally. We want to grow globally by strengthening our presence in the markets where we already are active and by establishing ourselves in new and interesting markets.
G2. Growing within transplantations. Glycorex has a strong position in living donor kidney transplantations. Our ambition is to strengthen our position in a number of other areas of transplantations.
G3. Growing beyond transplantations. Our technology holds fantastic opportunities for expansion into new areas and we have several products approaching the market. Immediately available is expansion into transfusion, followed by rheumatoid arthritis.
G4. Growing through innovations. Glycorex has demonstrated the ability to develop new products based on the company's unique technology. In addition to already served markets, there are several new areas of interest where Glycorex could play a crucial role in improving healthcare.
You can read more about our G4G strategy on pages 5-9 of the enclosed report.
The positive start to the year and our G4G ambitions as future targets make me look forward to 2022 with confidence.
CEO
For further information, please contact:
E-mail: info@glycorex.com, phone: 046-286 52 30
Brief information about the company
Glycosorb® ABO is one of
The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the
https://news.cision.com/glycorex-transplantation/r/quarterly-report--quarter-1-2022,c3573044
https://mb.cision.com/Main/15286/3573044/1583640.pdf
(c) 2022 Cision. All rights reserved., source